Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 27(18)2022 Sep 16.
Article in English | MEDLINE | ID: mdl-36144771

ABSTRACT

Cannabis-infused product manufacturers often add terpenes to enhance flavor. Meanwhile, labeling requirements for these same products necessitate testing for residual solvent levels. We have found that heating terpene samples containing an oxygen or air atmosphere results in the detection of significantly higher levels of acetone when compared to the same compound in argon atmosphere using temperature regimes common to headspace autosampler routines. This formation was statistically significant (p = 0.05) for most of the predominant terpenes found in cannabis. The largest increase in acetone formation was seen for terpinolene which showed an 885% increase in oxygen atmosphere (4603.6 PPM) when compared to analysis under argon (519.9 PPM). Cannabinoids were shown to reduce this formation and explain why high levels of acetone are not reported in cannabis extracts, even though these can contain up to 40% terpenes.


Subject(s)
Cannabinoids , Cannabis , Acetone , Argon , Artifacts , Cannabinoids/analysis , Oxygen , Solvents , Terpenes/analysis
2.
Article in English | MEDLINE | ID: mdl-19853429

ABSTRACT

Lipoxins (LXs) are potent endogenous counter-regulatory lipid mediators that dampen acute inflammation and promote its resolution. Here, we present our investigation of a new class of thermally and metabolically stable benzo-LXA(4) analogs that are potently anti-inflammatory and easier to synthesize. Replacement of the tetraene unit of native LXA(4) with a benzo-fused ring system not only increases the thermal stability but also enables highly convergent and efficient syntheses of these analogs. In addition, they resist rapid catalysis and inactivation by eicosanoid oxidoreductase. Like native LXs, o-[9, 12]-benzo-omega6-epi-LXA(4), o-[9, 12]-benzo-deoxy-LXA(4), m-[9, 12]-benzo-omega6-epi-LXA(4) and [9, 14]-benzo-omega6-(R/S)-LXA(4) demonstrated potent time-dependent reduction, at nanogram dosages, of PMN infiltration and pro-inflammatory cytokine generation in vivo in murine peritonitis and were organ protective in hind limb ischemia-reperfusion injury of the lung. The o-[9, 12]-benzo-omega6-epi-LXA(4) and m-[9, 12]-benzo-omega6-epi-LXA(4) were most potent in nanogram doses; both decreased PMN infiltration by approximately 32%, while o-[9, 12]-benzo-deoxy-LXA(4) and [9, 15]-omega6-(R/S)-LXA(4) were less potent. The [9,12]-benzo-omega6-epi-LXA(4) also activated a lipoxin A(4) GPCR and increased macrophage phagocytic activity. Taken together, these findings demonstrate a new generation of LXA(4) stable analogs that are easy to synthesize and anti-inflammatory. These benzo-LXA(4) analogs are promising tools for new therapeutic approaches as well as assessing endogenous mechanisms in anti-inflammation and resolution.


Subject(s)
Inflammation/drug therapy , Inflammation/prevention & control , Lipoxins/pharmacology , Lipoxins/therapeutic use , Acute Disease , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/metabolism , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Cells, Cultured , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Eicosanoids/metabolism , Eicosanoids/pharmacology , Eicosanoids/therapeutic use , Lipoxins/chemistry , Lipoxins/metabolism , Macrophage Activation/drug effects , Macrophages/drug effects , Macrophages/pathology , Male , Mice , Models, Biological , Peritonitis/drug therapy , Peritonitis/pathology , Receptors, Formyl Peptide/metabolism , Remission Induction
3.
Bioorg Med Chem Lett ; 18(4): 1382-7, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-18249111

ABSTRACT

A new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native LXA(4) with a substituted benzo-fused ring system have been designed and studied. These molecules were readily synthesized via a convergent synthetic route involving iterative palladium-mediated cross-coupling, and exhibit enhanced chemical stability, as well as resistance to metabolic inactivation via eicosanoid oxido-reductase. These new LX analogs were evaluated in a model of acute inflammation and were shown to exhibit potent anti-inflammatory properties, significantly decreasing neutrophil infiltration in vivo. The most potent among these was compound 9 (o-[9,12]-benzo-15-epi-LXA(4) methyl ester. Taken together, these findings help identify a new class of stable and easily prepared LX analogs that may serve as novel tools and as promising leads for new anti-inflammatory agents with improved therapeutic profile.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Benzene Derivatives/chemical synthesis , Benzene Derivatives/pharmacology , Lipoxins/chemical synthesis , Lipoxins/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Drug Design , Drug Stability , Lipoxins/chemistry , Lipoxins/metabolism , Mice , Neutrophil Infiltration/drug effects , Oxidoreductases/chemistry , Oxidoreductases/metabolism , Peritonitis/drug therapy
4.
J Exp Med ; 203(4): 857-63, 2006 Apr 17.
Article in English | MEDLINE | ID: mdl-16567384

ABSTRACT

Neutrophils play a central role in host defense, inflammation, and tissue injury. Recent findings indicate a novel role for polyisoprenyl phosphates (PIPPs) as natural down-regulatory signals in neutrophils. The relationship between PIPPs and neutrophil early activating signals, such as phosphoinositides, has not been previously determined. Here, we establish presqualene diphosphate (PSDP) as an endogenous PIPP regulator of phosphatidylinositol 3-kinase (PI3K). In human neutrophils, leukotriene B4 (LTB4) triggered rapid decreases in PSDP and reciprocal increases in PI3K activity. In addition, PSDP was identified by gas chromatography/mass spectrometry in p110gamma-PI3K immunoprecipitates obtained 30 s after LTB4, indicating a physical interaction between PSDP and PI3K in activated neutrophils. Moreover, PSDP (0.4-800 pmol) directly inhibited recombinant human p110gamma-PI3K activity. During an experimental model of lung injury and inflammation, a reciprocal relationship was also present in vivo for lung PSDP and PI3K activity. To investigate its therapeutic potential, we developed a new PSDP structural mimetic that blocked human neutrophil activation and mouse lung PI3K activity and inflammation. Together, our findings indicate that PSDP is an endogenous PI3K inhibitor, and suggest that in inflammatory diseases characterized by excessive neutrophil activation, PIPPs can serve as structural templates in a novel antineutrophil therapeutic strategy to limit tissue injury.


Subject(s)
Lung/enzymology , Lung/pathology , Neutrophils/enzymology , Neutrophils/pathology , Phosphatidylinositol 3-Kinases/metabolism , Polyisoprenyl Phosphates/pharmacology , Animals , Cells, Cultured , Humans , Lung/metabolism , Male , Mice , Neutrophil Activation , Neutrophils/metabolism , Phosphoinositide-3 Kinase Inhibitors , Reactive Oxygen Species/metabolism
5.
Article in English | MEDLINE | ID: mdl-16098719

ABSTRACT

The lipoxins (LX) are a class of potent endogenous oxygenated products that are enzymatically generated from arachidonic acid and have novel anti-inflammatory properties and promote resolution. Elucidation of the biochemical pathways involved in the metabolic inactivation of LX and the discovery of the aspirin-triggered lipoxins (ATL) provided the basis for the design and synthesis of stable analogs of LX and ATL. This special issue review describes the efforts that led to the design and synthesis of stable LX/ATL mimetics, which permitted the detailed elucidation of their novel biological roles, leading to the development of new anti-inflammatory agents that mimic their actions. These synthetic molecules provided the means to uncover the physiologic roles of both the LX and the ATL biosynthetic pathways which led to several unexpected discoveries. Among these findings is the involvement of polyisoprenyl phosphates (PIPP) in intracellular signaling mediated by presqualene diphosphate (PSDP), and the recognition of the novel roles of these lipid mediators in regulating cell trafficking during inflammation as well as in promoting resolution of inflammatory processes. These efforts also provided the basis for examining the potential therapeutic role of LX/ATL stable mimetics and led to the development of new analogs with improved pharmacokinetics that opened the way to potentially new approaches to treating human diseases.


Subject(s)
Drug Design , Inflammation/physiopathology , Lipoxins/chemical synthesis , Anti-Inflammatory Agents/pharmacology , Aspirin/pharmacology , Eicosanoids/biosynthesis , Humans , Lipoxins/metabolism , Lipoxins/therapeutic use , Molecular Structure
6.
Br J Pharmacol ; 146(3): 344-51, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16041402

ABSTRACT

Leukocyte production of reactive oxygen species (ROS) is an essential component of the antimicrobial armament mounted during host defense, but when released to the extracellular milieu ROS can also injure host tissues and provoke inflammation. Polyisoprenyl phosphates (PIPPs) are constituents of human leukocyte membranes that regulate pivotal intracellular enzymes, such as phospholipase D (PLD). We prepared new PIPP mimetics and studied their impact in vivo on leukocyte activation, including ROS generation, in acute inflammation. In a stereospecific and concentration-dependent manner, the PIPP mimetics directly regulated Streptomyces chromofuscus phospholipase D (sPLD) action. The IC(50) for a (Z)-isomer of endogenous presqualene diphosphate (PSDP) was 100 nM. Structure-activity relationships were also determined for PIPP mimetic inhibition of recombinant human PLD1b, a prominent isoform in human leukocytes. The PIPP mimetic rank order for PLD1b inhibition differed from sPLD, although the (Z)-PSDP isomer remained the most potent PIPP mimetic for inhibition of both enzymes. Truncation of PLD1b to its catalytic core uncovered potential regulatory roles for both PSDP's isoprenoid and diphosphate moieties. The (Z)-PSDP isomer reduced ROS production by activated human leukocytes and decreased murine neutrophil accumulation (65.6%) and ROS production (38.5%) in vivo during zymosan A-initiated peritonitis. When administered intraperitoneally 2 h after zymosan A, the (Z)-PSDP isomer decreased in vivo neutrophil accumulation (72.5%) and ROS generation (74.4%) 6 h later in peritoneal exudates. Together, these results provide new means to protect and control unchecked inflammatory responses that characterize many human diseases.


Subject(s)
Neutrophils/drug effects , Peritonitis/metabolism , Phospholipase D/metabolism , Polyisoprenyl Phosphates/pharmacology , Animals , Computer Simulation , Humans , In Vitro Techniques , Male , Mice , Mice, Inbred Strains , Models, Molecular , Neutrophil Activation/drug effects , Neutrophils/immunology , Neutrophils/metabolism , Peritonitis/chemically induced , Peritonitis/immunology , Phospholipase D/antagonists & inhibitors , Polyisoprenyl Phosphates/chemistry , Reactive Oxygen Species/metabolism , Structure-Activity Relationship , Zymosan
7.
Nat Immunol ; 5(4): 388-92, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15034576

ABSTRACT

In cystic fibrosis, dysregulated neutrophilic inflammation and chronic infection lead to progressive destruction of the airways. The underlying mechanisms have remained unclear. Lipoxins are anti-inflammatory lipid mediators that modulate neutrophilic inflammation. We report here that lipoxin concentrations in airway fluid were significantly suppressed in patients with cystic fibrosis compared to patients with other inflammatory lung conditions. We also show that administration of a metabolically stable lipoxin analog in a mouse model of the chronic airway inflammation and infection associated with cystic fibrosis suppressed neutrophilic inflammation, decreased pulmonary bacterial burden and attenuated disease severity. These findings suggest that there is a pathophysiologically important defect in lipoxin-mediated anti-inflammatory activity in the cystic fibrosis lung and that lipoxins have therapeutic potential in this lethal autosomal disease.


Subject(s)
Cystic Fibrosis/metabolism , Inflammation/metabolism , Lipoxins/metabolism , Respiratory System/metabolism , Epithelium/metabolism , Humans , Respiratory Tract Infections/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...